|
Presentation |
Webcast |
November 24, 2022
Redeye Life Science Day 2022 - In Focus Q&A
|
|
|
October 6, 2022
Presentation at Redeye Investor AW in Gothenburg
|
|
|
September 22, 2022
Deep dive presentation on the positive feedback from the Japanese regulatory authority (PMDA) on cobitolimod
|
|
|
June 9, 2022
Deep dive presentation on the commercialization strategy for cobitolimod
|
|
|
June 2, 2022
Redeye Growth Day 2022 In Focus Q&A
|
|
|
May 16, 2022
Q1 report interview with acting CEO Johan Giléus
|
|
|
March 31, 2022
Presentation at Redeye Investor Forum in Malmö
|
|
|
March 14, 2022
Capital Markets Day 2022
|
|
|
February 28, 2022
Deep dive into the mechanism of action of cobitolimod with CEO Peter Zerhouni and Senior Scientist Charlotte Admyre
|
|
|
February 25, 2022
Year-end report Interview with CEO Peter Zerhouni
|
|
|
January 27, 2022
CEO Peter Zerhouni and CMO Thomas Knittel make a deep dive into the design of the phase III study CONCLUDE
|
|
|